Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: The European APL group experience

Journal of Clinical Oncology

Volumn 27, Issue 16, 2009, Pages 2668-2676

  Kelaidi, Charikleia ^a   Chevret, Sylvie ^a   De Botton, Stéphane ^a   Raffoux, Emmanuel ^a   Guerci, Agnès ^a   Thomas, Xavier ^a   Pigneux, Arnaud ^a   Lamy, Thierry ^a   Rigal Huguet, Françoise ^a   Meyer Monard, Sandrine ^a   Chevallier, Patrice ^a   Maloisel, Frédéric ^a   Deconinck, Erick ^a   Ferrant, Augustin ^a   Fegueux, Nathalie ^a   Ifrah, Norbert ^a   Sanz, Miguel ^a   Dombret, Hervé ^a   Fenaux, Pierre ^a   Adès, Lionel ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; RETINOIC ACID; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; DRUG DOSE ESCALATION; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; ADOLESCENT; AGED; BLOOD; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EUROPE; HEALTH CARE QUALITY; INFANT; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HUMANS; INFANT; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; QUALITY OF HEALTH CARE; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 66849103735     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.4119     Document Type: Article

References (43)

1. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol 33:451-458, 1976
2. Larson RA, Kondo K, Vardiman JW, et al: Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 76: 827-841, 1984
3. de Thé H, Lavau C, Marchio A, et al: The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66:675-684, 1991
4. Kakizuka A, Miller WH Jr, Umesono K, et al: Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66: 663-674, 1991
5. Huang ME, Ye YC, Chen SR, et al: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567-572, 1988
6. Castaigne S, Chomienne C, Daniel MT, et al: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia: I. Clinical results. Blood 76:1704-1709, 1990
7. Chomienne C, Ballerini P, Balitrand N, et al: All-trans retinoic acid in acute promyelocytic leukemias: II. In vitro studies: Structure-function relationship. Blood 76:1710-1717, 1990
8. Wang ZY, Chen Z: Acute promyelocytic leukemia: From highly fatal to highly curable. Blood 111:2505-2515, 2008
9. Marty M, Ganem G, Fischer J, et al: Acute promyelocytic leukemia: Retrospective study of 119 patients treated with daunorubicin. Nouv Rev Fr Hematol 26:371-378, 1984
10. Cunningham I, Gee TS, Reich LM, et al: Acute promyelocytic leukemia: Treatment results during a decade at Memorial Hospital. Blood 73:1116-1122, 1989
11. Fenaux P, Le Deley MC, Castaigne S, et al: Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia: Results of a multicenter randomized trial - European APL 91 Group. Blood 82:3241-3249, 1993
12. Fenaux P, Chevret S, Guerci A, et al: Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia: European APL group. Leukemia 14:1371-1377, 2000
13. Fenaux P, Chastang C, Chevret S, et al: A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia: The European APL Group. Blood 94:1192-1200, 1999
14. Asou N, Adachi K, Tamura J, et al: Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy: Japan Adult Leukemia Study Group. J Clin Oncol 16:78-85, 1998
15. Burnett AK, Grimwade D, Solomon E, et al: Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the Randomized MRC Trial. Blood 93:4131-4143, 1999
16. Sanz MA, Martin G, Rayon C, et al: A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia: PETHEMA group. Blood 94: 3015-3021, 1999
17. Avvisati G, Petti MC, Lo-Coco F, et al: Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood 100:3141-3146, 2002
18. Sanz MA, Martin G, Gonzalez M, et al: Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA group. Blood 103:1237-1243, 2004
19. Tallman MS, Andersen JW, Schiffer CA, et al: All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100:4298-4302, 2002
20. Adès L, Chevret S, Raffoux E, et al: Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Group. J Clin Oncol 24:5703-5710, 2006
21. Callens C, Chevret S, Cayuela JM, et al: Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): A retrospective study from the European APL Group. Leukemia 19:1153-1160, 2005
22. Sanz MA, Lo Coco F, Martin G, et al: Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247-1253, 2000
23. Sanz MA, Montesinos P, Vellenga E, et al: Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: Long-term outcome of the LPA 99 multicenter study by the PETHEMA group. Blood 112:3130-3134, 2008
24. Cheson B, Cassileth P, Head D, et al: Report of the national cancer institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990
25. Kaplan E, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
26. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
27. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc A 135:185-198, 1972
28. Gray R: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1998
29. Fine J, Gray R: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
30. De Botton S, Dombret H, Sanz M, et al: Incidence, clinical features, and outcome of all transretinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia: The European APL Group. Blood 92:2712-2718, 1998
31. Fenaux P, Pollet J, Vandenbossche L, et al: Treatment of acute promyelocytic leukemia: A report on 70 cases. Leuk Lymphoma 4:239-248, 1991
32. Kantarjian HH, Keating MJ, Walters RS, et al: Acute promyelocytic leukemia: M.D. Anderson Hospital experience. Am J Med 80:789-797, 1986
33. Sanz MA, Jarque I, Martín G, et al: Acute promyelocytic leukemia: Therapy results and prognostic factors. Cancer 61:7-13, 1988
34. Lengfelder E, Reichert A, Schoch C, et al: Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: Effects in patients with newly diagnosed acute promyelocytic leukemia - German AML Cooperative Group. Leukemia 14:1362-1370, 2000
35. Lo Coco F, Avvisati G, Vignetti M, et al: Frontline treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation: Results of the AIDA-2000 trial of the Italian GIMEMA group. Blood 104:11, 2004 (abstr 392)
36. Adès L, Sanz MA, Chevret S, et al: Treatment of newly diagnosed acute promyelocytic leukemia (APL): A comparison of French-Belgian-Swiss and PETHEMA results. Blood 111:1078-1084, 2008
37. Schlenk RF, Germing U, Hartmann F, et al: High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia 19:978-983, 2005
38. Reference has been deleted
39. Estey EH, Giles FJ, Beran M, et al: Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 99:4222-4224, 2002
40. Lo-Coco F, Cimino G, Breccia M, et al: Mylotarg as single agent for molecularly relapsed acute promyelocytic leukemia. Blood 104:1995-1999, 2004
41. Shen ZX, Shi ZZ, Fang J, et al: All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 101: 5328-5335, 2004
42. Mathews V, George B, Lakshmi KM, et al: Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood 107:2627-2632, 2006
43. Powell BL, Moser B, Stock W, et al: Effect of consolidation with Arsenic Trioxyde on event-free survival and overall survival among patients with newly diagnosed acute promyelocytic leukemia: North American Intergroup Protocol C9710. J Clin Oncol 25:18s, 2007 (suppl; abstr 2